Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network

Affiliations

¹ Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
² Department of Dermatology, University Medical Center Goettingen, Germany.
³ Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University Bochum, Minden, Germany.
⁴ Department of Dermatology, University Hospital Mannheim, Germany.
⁵ Department of Dermatology, University Hospital Würzburg, Germany.
⁶ Department of Dermatology, Ludwigshafen, Germany.
⁷ Hautklinik, Städtisches Klinikum Karlsruhe, Akademisches Lehrkrankenhaus der Universität Freiburg, Karlsruhe, Germany.
⁸ Department of Dermatology, Vivantes Klinikum Neukölln, Berlin, Germany.
⁹ Department of Dermatology, University Hospital Zurich, Switzerland.
¹⁰ Kempf und Pfaltz Histologische Diagnostik, Zurich, Switzerland.
¹¹ Department of Dermatology, Helios-Klinikum Krefeld, Germany.

U Wehkamp et al. Br J Dermatol. 2021 Jul.

. 2021 Jul;185(1):228-230.

doi: 10.1111/bjd.19823. Epub 2021 May 7.

¹ Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
² Department of Dermatology, University Medical Center Goettingen, Germany.
³ Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University Bochum, Minden, Germany.
⁴ Department of Dermatology, University Hospital Mannheim, Germany.
⁵ Department of Dermatology, University Hospital Würzburg, Germany.
⁶ Department of Dermatology, Ludwigshafen, Germany.
⁷ Hautklinik, Städtisches Klinikum Karlsruhe, Akademisches Lehrkrankenhaus der Universität Freiburg, Karlsruhe, Germany.
⁸ Department of Dermatology, Vivantes Klinikum Neukölln, Berlin, Germany.
⁹ Department of Dermatology, University Hospital Zurich, Switzerland.
¹⁰ Kempf und Pfaltz Histologische Diagnostik, Zurich, Switzerland.
¹¹ Department of Dermatology, Helios-Klinikum Krefeld, Germany.

No abstract available

References

1. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature 1982; 299:65-7.
1. Kim YH, Tavallaee M, Sundram U et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol 2015; 33:3750-8.
1. Mahévas T, Ram-Wolff C, Battistella M et al. Dramatic response to brentuximab vedotin in a refractory nontransformed CD30- mycosis fungoides allowing allogeneic stem cell transplantation and long-term complete remission. Br J Dermatol 2019; 180:1517-20.
1. Zhang C, Chairatchaneeboon M, Haun P et al. Treatment of CD30-negative refractory mycosis fungoides with brentuximab vedotin. JAMA Dermatol 2018; 154:109-10.
1. Gru AA, Kim J, Pulitzer M et al. The use of central pathology review with digital slide scanning in advanced-stage mycosis fungoides and Sezary syndrome: a multi-institutional and international pathology study. Am J Surg Pathol 2018; 42:726-34.